PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 1885 (106th)

International Prescription Drug Parity Act

openUnited States· United States Congress· EN

Introduced

20 May 1999

Last action

12 April 2000 · Introduced

Status

Sponsor introductory remarks on measure. (CR H2186-2187)

Sponsors

Rep. Berry, Marion [D-AR-1], Sen. Sanders, Bernard [I-VT], Rep. Emerson, Jo Ann [R-MO-8], DANA ROHRABACHER, Rep. Abercrombie, Neil [D-HI-1], JOHN LEWIS, Rep. Shows, Ronnie [D-MS-4], Rep. Baker, Richard H. [R-LA-6], Rep. Strickland, Ted [D-OH-6], Rep. Stark, Fortney Pete [D-CA-9], Rep. Barrett, Thomas M. [D-WI-5], Rep. Weiner, Anthony D. [D-NY-9], Rep. Delahunt, Bill [D-MA-10], Rep. Hoekstra, Peter [R-MI-2], Rep. Kilpatrick, Carolyn C. [D-MI-13], Rep. Kucinich, Dennis J. [D-OH-10], Rep. Allen, Thomas H. [D-ME-1], Rep. Hinchey, Maurice D. [D-NY-22], PETER DEFAZIO, Rep. Luther, Bill [D-MN-6], Rep. Hutchinson, Asa [R-AR-3], LOUISE SLAUGHTER, Rep. Baldacci, John Elias [D-ME-2], Rep. Bereuter, Doug [R-NE-1], Rep. Vento, Bruce F. [D-MN-4], Sen. Brown, Sherrod [D-OH], Rep. Hilliard, Earl F. [D-AL-7], Rep. Sandlin, Max [D-TX-1], Rep. Boswell, Leonard L. [D-IA-3], Rep. Hooley, Darlene [D-OR-5], Rep. Martinez, Matthew G. [D-CA-30], Rep. Cramer, Robert E. (Bud), Jr. [D-AL-5], Rep. Hinojosa, Ruben [D-TX-15], Sheila Jackson Lee, Rep. Schakowsky, Janice D. [D-IL-9], Rep. LaFalce, John J. [D-NY-36], Rep. Rivers, Lynn N. [D-MI-13], Rep. Campbell, Tom [R-CA-12], Rep. McHugh, John M. [R-NY-23], Rep. Olver, John W. [D-MA-1], Sen. Baldwin, Tammy [D-WI], John Larson, Rep. Filner, Bob [D-CA-51], Rep. Nadler, Jerrold [D-NY-12], JOHN CONYERS, Rep. Millender-McDonald, Juanita [D-CA-37], Rep. McKinney, Cynthia A. [D-GA-4], Rep. Capps, Lois [D-CA-24]

Subjects

Healthcare

Source updated

3 June 2026

Healthcare

Summary

International Prescription Drug Parity Act - Amends the Federal Food, Drug, and Cosmetic Act to require manufacturers of certain drugs manufactured and domestically approved and then exported, or domestically approved and manufactured in a registered foreign establishment, to: (1) maintain specified shipment compliance and labeling records; and (2) make such records available to U.S. importers. Directs the Secretary of Health and Human Services to establish related criteria to facilitate the U.S. importation of such drugs.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 20 May 1999

    Introduced

    Referred to the House Committee on Commerce.

    Source: IntroReferral

  2. 20 May 1999

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 20 May 1999

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 15 June 1999

    Referred

    Referred to the Subcommittee on Health and Environment.

    Source: Committee

  5. 12 April 2000

    Introduced

    Sponsor introductory remarks on measure. (CR H2186-2187)

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

Sponsors

Showing 48 of 97 sponsors and actors.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.